Drug news
EU approves Prevnar 13 for Pneumococcal Disease in adults aged 50 years and older
The European Commission has approved the pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) from Pfizer for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older a time of life when the risk for contracting the disease begins to increase.The vaccine is filed at the FDA for the same indication.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins